Single-dose and steady state pharmacokinetics of CsA and two main primary metabolites, AM1 and AM4N in patients with rheumatic/autoimmune diseases

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F11%3A00102152" target="_blank" >RIV/00843989:_____/11:00102152 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61988987:17110/11:A12013LV

Výsledek na webu

<a href="http://dx.doi.org/10.5507/bp.2011.020" target="_blank" >http://dx.doi.org/10.5507/bp.2011.020</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5507/bp.2011.020" target="_blank" >10.5507/bp.2011.020</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Single-dose and steady state pharmacokinetics of CsA and two main primary metabolites, AM1 and AM4N in patients with rheumatic/autoimmune diseases

Popis výsledku v původním jazyce

Background. Cyclosporine A (CsA) is an immunomodulatory agent used in standard immunosuppressive regimens in solid organ transplantations as well as in the treatment of autoimmune diseases such as rheumatoid arthritis (RA), systemic lupus and psoriasis.Its immunosuppressive activity is primarily due to parent drug. However, following oral administration, absorption is incomplete and varies between individuals. Further, there is a dearth of pharmacokinetic data for CsA in autoimmune patients compared totransplant recipients. Aim. The goal of this study was to investigate the single-dose and steady state pharmacokinetics of CsA and two main primary metabolites, AM1 and AM4N, in patients with rheumatic/autoimmune diseases. Methods. Thirty-eight subjects, average age (years +/- SD) 46.8 (+/- 11.6) years with rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, ankylosing spondylitis and undifferentiated SpA were included in an observational open study. The single dose

Název v anglickém jazyce

Single-dose and steady state pharmacokinetics of CsA and two main primary metabolites, AM1 and AM4N in patients with rheumatic/autoimmune diseases

Popis výsledku anglicky

Background. Cyclosporine A (CsA) is an immunomodulatory agent used in standard immunosuppressive regimens in solid organ transplantations as well as in the treatment of autoimmune diseases such as rheumatoid arthritis (RA), systemic lupus and psoriasis.Its immunosuppressive activity is primarily due to parent drug. However, following oral administration, absorption is incomplete and varies between individuals. Further, there is a dearth of pharmacokinetic data for CsA in autoimmune patients compared totransplant recipients. Aim. The goal of this study was to investigate the single-dose and steady state pharmacokinetics of CsA and two main primary metabolites, AM1 and AM4N, in patients with rheumatic/autoimmune diseases. Methods. Thirty-eight subjects, average age (years +/- SD) 46.8 (+/- 11.6) years with rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, ankylosing spondylitis and undifferentiated SpA were included in an observational open study. The single dose

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FR - Farmakologie a lékárnická chemie

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Biomedical papers

ISSN

1213-8118

e-ISSN

—

Svazek periodika

155

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

6

Strana od-do

269-274

Kód UT WoS článku

000297807500008

EID výsledku v databázi Scopus

—